Opus Genetics, Inc. (IRD)
NASDAQ · Manufacturing · Pharmaceutical preparations
$4.71−$0.1594 (−3.27%) on the dayAs of the close; data may be delayed.
IRD price, last 12 months
Key stats
- Previous close
- $4.87
- Open
- $4.86
- Day range
- $4.70 – $4.95
- 52-week range
- $1.50 – $7.07
- Volume
- 1.1M
- Avg volume (20 days)
- 5.2M
- Market cap
- $396.0M
Performance
1W−9.1%
1M+24.0%
3M+17.8%
6M+4.2%
YTD+134.4%
1Y+187.2%
vs S&P 500, 1Y+170.5 pts
Technicals and fundamentals
About Opus Genetics, Inc.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $396.0M